Related references
Note: Only part of the references are listed.Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
John A. Spertus et al.
LANCET (2021)
Phenotypic Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic Cardiomyopathy
Antonio de Marvao et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Iacopo Olivotto et al.
LANCET (2020)
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Steve R. Ommen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity
Arjun S. Adhikari et al.
NATURE COMMUNICATIONS (2019)
Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States
Martin S. Maron et al.
AMERICAN JOURNAL OF CARDIOLOGY (2016)
Hypertrophic Cardiomyopathy Present and Future, With Translation Into Contemporary Cardiovascular Medicine
Barry J. Maron et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Bernard J. Gersh et al.
CIRCULATION (2011)
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy
MS Maron et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
